NCT02706405 2022-08-24JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaFred Hutchinson Cancer CenterPhase 1 Terminated30 enrolled 29 charts
NCT03685344 2021-10-26Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular LymphomaADC Therapeutics S.A.Phase 1 Terminated13 enrolled 15 charts